key: cord-0800892-f2tkznco
authors: Ghalamkarpour, Fariba; Pourani, Mohammad Reza
title: Aggressive course of pemphigus vulgaris following COVID‐19 infection
date: 2020-10-10
journal: Dermatol Ther
DOI: 10.1111/dth.14398
sha: 97d279d4c326c7c3218710ba2cea6e7c27490a92
doc_id: 800892
cord_uid: f2tkznco

nan

Dermatologists have experienced many challenges in management of autoimmune disorders such as pemphigus vulgaris during COVID-19 pandemic era . 1 A 40-year-old female presented with bullae and erosions since 50 days ago ( Figure 1A ). In physical examination multiple bullae and erosions were seen on her scalp, trunk, upper and lower limbs. Mucosal surfaces were intact. Skin biopsy for routine histopathology and immunofluorescence examinations were done and diagnosis of pemphigus vulgaris was confirmed. We planned to start rituximab; therefore, all required examinations were checked for her. Evaluation for COVID-19 showed negative polymerase chain reaction (PCR) test result and normal chest CT scan. Meanwhile, PPD test with 18mm induration and a positive Interferon Gamma Release Assay (IGRA) were reported. According to infectious disease consultation, treatment with isoniazid 300mg/d and B6 tablet were started for her. Soon she was hospitalized at dermatology ward that all patients had negative COVID-19 test results, and received 1g rituximab without systemic steroid as adjuvant. She was discharged without any exposures to COVID-19 patients, and recommended to isolate at home. Few days later, the patient came back showing a rapidly aggressive course with involvement of nasal mucosa and appearance of multiple bullae on her skin [Total activity score: 34, based on pemphigus disease area index (PDAI)] ( Figure 1B) . A second COVID-19 PCR test was done and meanwhile 0.5 mg/kg (40 mg) prednisolone daily was added to her treatment schedule. Her PCR test result was positive this time; consequently, we changed her treatment plan to IVIG 25g/d for 5 days. Within the first two days of IVIg treatment, appearance of new lesions stopped ( Figure 1C ). Skin lesions started to dry and epithelialization appeared to start. Her general condition improved in a week. She was discharged, but few days later she noticed blurred vision. Ocular herpes was diagnosed for her and acyclovir 2g daily for ten days was administered immediately. Two weeks later, in a followup visit her symptoms and skin lesions were ameliorated significantly ( Figure 2 ).

Severe cases of pemphigus vulgaris are life threatening and may cause mortality rate of 10%. 2

Most studies suggest combining rituximab with low-dose prednisolone in treatment of pemphigus vulgaris. 3-6 However, In this patient we did not use any systemic steroid due to positive IGRA and the risk of COVID 19 infection; although we added oral prednisolone later in order to prevent further progression of the disease. One of the main concerns in rituximab application is hospitalization, and it should be administered in a unit outside the wards that are treating COVID-19 patients. Exacerbation of lesions secondary to administration of rituximab has been reported but COVID-19 positivity is highly suspected in this case. 7 We replaced her treatment protocol with IVIg. In cases of pemphigus vulgaris associated with COVID-19 infection IVIg is the treatment of choice. 4-6 Our patient was controlled with this treatment. Further investigations are needed to evaluate the most appropriate treatment schedule for pemphigus vulgaris in the COVID-19 pandemic.

This article is protected by copyright. All rights reserved.

Advice regarding COVID-19 and use of